OS THERAPIES

NYSE American: **OSTX**

REDCHIP

Market Data

OS Therapies, Inc.

NYSE American: **OSTX**

Fiscal Year	December
Industry	Biopharma
Recent Price	$3.12
Market Cap	$52.5M
Shares Out.	21.2M
Insider Ownership	33.4%
Float	14.1M
Cash (mrq)	$1.9M

Price data as of January 21, 2025

ostherapies.com

Strong support from OS community

THE OSTEOSARCOMA COLLABORATIVE
Working Together To Find A Cure

Children's Cancer Research Fund®

osteosarcoma INSTITUTE
concentrating on the cure

CHILDREN'S ONCOLOGY GROUP

Canines-N-Kids FOUNDATION
Crush cancer @ BOTH ends of the leash

Company Overview

OS Therapies is a clinical-stage biopharmaceutical company pioneering innovative treatments for osteosarcoma (OS), HER2-positive cancers, and other solid tumors. With a focus on addressing unmet needs in pediatric and young adult oncology, the company's lead candidate, OST-HER2, is a groundbreaking immunotherapy that has shown statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic OS. OST-HER2 leverages a bioengineered Listeria monocytogenes strain to activate targeted immune responses, offering hope in an area where no new FDA-approved treatments have emerged in over 40 years.

Complementing OST-HER2, OS Therapies is advancing its next-generation Tunable Antibody Drug Conjugate (tADC) platform, powered by proprietary SiLinker™ technology. This innovative platform delivers precision-targeted payloads, creating opportunities to address challenging cancers such as ovarian, breast, and gastric tumors. By targeting high-impact areas within oncology, OS Therapies is positioned to deliver transformative solutions for patients with limited treatment options.

Investment Highlights

Groundbreaking immunotherapy with regulatory momentum

- OST-HER2 demonstrated statistically significant improvements in 12-month event-free survival (EFS) for recurrent, fully resected metastatic osteosarcoma patients
- Positioned for accelerated FDA approval with Rare Pediatric Disease, Orphan Drug, and Fast Track Designations
- Potential Priority Review Voucher (PRV), valued at approximately $150 million, upon FDA approval

Innovative next-generation ADC technology

- Tunable ADC (tADC) platform powered by proprietary SiLinker™ technology enables precise delivery of multiple payloads to tumors
- Preclinical success with OST-tADC-FRA-H demonstrated strong efficacy and safety in ovarian cancer models
- Broad applications across HER2-positive and other solid tumors, creating significant licensing and development opportunities

Large and diverse market opportunities

- Addressable markets include $1.2 billion for human osteosarcoma (adult and pediatric), $150 million for canine osteosarcoma, and $55 billion for HER2-positive solid tumors
- ADC technology addresses the broader cancer treatment market, including chemotherapy and immunotherapies, with a market projected to grow to $20.9 billion by 2030

Compelling near-term catalysts

- Engaging FDA on accelerated approval pathway for OST-HER2 in osteosarcoma following successful Phase 2b clinical trial results
- Potential revenue streams from PRV sale, licensing agreements for canine and human osteosarcoma, and out-licensing SiLinker™ technology
- Strategic partnerships under discussion to expand OST-HER2 applications and accelerate commercialization

Strong leadership and industry recognition

- Veteran team with proven expertise in drug development, commercialization, and partnerships, including recent additions with decades of biopharma experience
- Participation in Johnson & Johnson's JLABS innovation network highlights the company's strong reputation and growth potential

Therapeutic Pipeline

Advanced Catalyst Rich OS Pipeline w/Large tADC Opportunity



*** FDA may grant OST-HER2 accelerated approval in OS based on Phase 2b data**

Value Proposition

OS Therapies is a clinical-stage biopharmaceutical company committed to transforming cancer care with innovative immunotherapies and antibody-drug conjugates (ADCs). Focused on addressing unmet needs in pediatric and young adult oncology, OS Therapies leads with its groundbreaking candidate, OST-HER2. This HER2-targeted immunotherapy has demonstrated statistically significant improvements in 12-month event-free survival for patients with recurrent, fully resected, metastatic osteosarcoma, an area with no FDA-approved therapies. The therapy's strong safety profile and promising overall survival data position it as a potential first-in-class treatment for this devastating disease.

In addition to OST-HER2, OS Therapies is advancing its proprietary tunable ADC platform (tADC), powered by SiLinker™ technology. This next-generation approach enables the delivery of multiple therapeutic payloads with precision, targeting a range of cancers including ovarian, breast, and gastric. Recent preclinical data from OST-tADC-FRA-H, the first tADC candidate, demonstrated significant efficacy and safety in ovarian cancer models, underscoring the platform's potential to revolutionize ADC development.

The company addresses large total addressable markets (TAMs), including $1.7 billion for human osteosarcoma (adult and pediatric) and $150 million for canine osteosarcoma. OST-HER2 also has potential applications in HER2-expressing solid tumors, a $55 billion market encompassing breast, gastric, and colorectal cancers. Additionally, OS Therapies' tunable ADC (tADC) platform, powered by SiLinker™ technology, represents an opportunity to target the broader cancer treatment market, including chemotherapy and immunotherapies.

With multiple upcoming milestones, including FDA discussions for accelerated approval of OST-HER2 and potential revenue from the sale of a Priority Review Voucher (PRV), OS Therapies is poised for key catalytic events. Combined with a robust pipeline and a seasoned leadership team, OS Therapies is uniquely positioned to deliver life-saving therapies while creating significant value for patients and investors alike.